← Back to Search

Monoclonal Antibodies

Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

Phase 2

Waitlist Available

Research Sponsored by PDL BioPharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Progression of disease or no response since last treatment for NHL

Bidimensionally measurable disease at least 2 cm in a single dimension

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare two different monoclonal antibody regimens to see which is more effective in treating patients with relapsed or refractory non-Hodgkin's lymphoma.

Who is the study for?

This trial is for patients with relapsed or refractory non-Hodgkin's lymphoma who have measurable disease and less than 5,000 tumor cells/mm^3 in their blood. They must have had prior treatments like radiotherapy or chemotherapy. People living outside the US, with a history of other lymphoproliferative disorders, active cancers, or any cancer within the last five years (except certain skin cancers) cannot join.Check my eligibility

What is being tested?

The study is testing two different monoclonal antibody therapies to see which one is more effective in treating non-Hodgkin's lymphoma that has either returned after treatment or hasn't responded to previous treatments. It's a phase II trial where patients are randomly assigned to receive one of the two regimens.See study design

What are the potential side effects?

Monoclonal antibodies may cause side effects such as allergic reactions at the infusion site, fever, chills, weakness, nausea, vomiting and can potentially harm normal cells while targeting cancer cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My non-Hodgkin lymphoma has not improved or has worsened since my last treatment.

Select...

My cancer can be measured and is at least 2 cm big in one direction.

Select...

My lymphoma is 1D10+ as confirmed by specific tests.

Select...

My cancer has not spread to my brain.

Select...

I am able to get out of my bed or chair and move around.

Select...

I haven't had any cancer except for skin cancer or early-stage cancer in the last 2 years.

Select...

I do not have major psychiatric or brain function issues.

Select...

I am 18 years old or older.

Select...

My heart condition does not severely limit my daily activities.

Select...

My neutrophil count is at least 1,000/mm^3.

Select...

I do not have any serious lung problems.

Select...

My lymphoma has returned or didn't respond to treatment.

Select...

I have had treatments like radiotherapy, immunotherapy, or chemotherapy for non-Hodgkin lymphoma.

Select...

I do not have any serious infections.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 14Eligibility criteria met

Find a Location

Who is running the clinical trial?

PDL BioPharma, Inc.Lead Sponsor

12 Previous Clinical Trials

1,197 Total Patients Enrolled

Tillman Pearce, MDStudy ChairFacet Biotech

2 Previous Clinical Trials

276 Total Patients Enrolled

Media Library

Monoclonal Antibody Therapy (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00014664 — Phase 2

Lymphoma Clinical Trial 2023: Monoclonal Antibody Therapy Highlights & Side Effects. Trial Name: NCT00014664 — Phase 2

Monoclonal Antibody Therapy (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00014664 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the risk-benefit ratio of this medical treatment?

"With the available data, our team at Power evaluated this treatment's safety to be a 2. This assessment is based on the fact that it has only reached Phase 2 clinical trials, providing some evidence of its security but no proof of effectiveness."

Answered by AI

Is this research actively looking for participants?

"Per the clinicaltrials.gov platform, this medical trial is not currently seeking out patients for participation. Initially posted on October 1st 2000 and last updated December 17th 2013, it does not require any new volunteers as of now. Fortunately, there are a plethora of similar trials recruiting participants at present; over 1750 in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

2000. "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00014664.

All > Childhood Leukemia > Lymphoma